Table 1. Clinico-pathological characteristics of patients in the study cohort.
| Age at Dx (Years) | Patients | % | n |
|---|---|---|---|
| Mean | 55 | 100 | 327* |
| Range | 29–85 | ||
| Tumor Size (mm) | |||
| Mean | 18.1 | 100 | 316 |
| Range | 2.5–57 | ||
| Tumor Grade | |||
| 1 | 64 | 20.7 | 309 |
| 2 | 196 | 63.4 | |
| 3 | 49 | 15.8 | |
| Tumor Nuclear Grade | |||
| 1 | 32 | 10.3 | 309 |
| 2 | 172 | 55.6 | |
| 3 | 105 | 33.9 | |
| Tumor Differentiation | |||
| 1 | 31 | 10 | 309 |
| 2 | 88 | 28.4 | |
| 3 | 190 | 61.4 | |
| Tumor ER Intensity | |||
| Weak | 8 | 3.2 | 244 |
| Moderate | 13 | 5.3 | |
| Strong | 223 | 91.3 | |
| Tumor PgR Intensity | |||
| Weak | 14 | 6.1 | 228 |
| Moderate | 65 | 28.5 | |
| Strong | 149 | 65.3 | |
| Recurrence Score | |||
| Low (<18) | 185 | 56.4 | 328 |
| Intermediate (18–30) | 110 | 33.6 | |
| High (>30) | 33 | 10.0 |
*: Age at Dx not available for one patient. ER, estrogen receptor; PgR, progesterone receptor